Peptide Receptor Radionuclide Therapy.
177Lu-DOTATATE
PRRT
neuroendocrine
peptide receptor radionuclide therapy
tumor
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
25 11 2022
25 11 2022
Historique:
received:
02
08
2022
pubmed:
6
10
2022
medline:
29
11
2022
entrez:
5
10
2022
Statut:
ppublish
Résumé
The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide termed "theranostics." Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second/third-line theranostic treatment for somatostatin receptor-positive well-differentiated (neuro-)endocrine neoplasms (NENs). PRRT with 177Lu-DOTATATE was approved by the regulatory authorities in 2017 and 2018 for selected patients with low-grade well-differentiated gastroenteropancreatic (GEP) NENs. It improves progression-free survival as well as quality of life of GEP NEN patients. Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have also been reported in patients with functioning metastatic GEP NENs like metastatic insulinomas, Verner Morrison syndromes (VIPomas), glucagonomas, and gastrinomas and patients with carcinoid syndrome. This therapy might also become a valuable therapeutic option for inoperable low-grade bronchopulmonary NENs, inoperable or progressive pheochromocytomas and paragangliomas, and medullary thyroid carcinomas. First-line PRRT with 177Lu-DOTATATE and combinations of this therapy with cytotoxic drugs are currently under investigation. New radiolabeled somatostatin receptor ligands include SSAs coupled with alpha radiation emitting radionuclides and somatostatin receptor antagonists coupled with radionuclides.
Identifiants
pubmed: 36198028
pii: 6748972
doi: 10.1210/clinem/dgac574
pmc: PMC9693835
doi:
Substances chimiques
Receptors, Somatostatin
0
copper dotatate CU-64
0
Octreotide
RWM8CCW8GP
Organometallic Compounds
0
Somatostatin
51110-01-1
Radioisotopes
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3199-3208Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
Références
JAMA Netw Open. 2022 Feb 1;5(2):e220290
pubmed: 35201309
Cancers (Basel). 2022 May 19;14(10):
pubmed: 35626105
Eur J Nucl Med. 1999 Nov;26(11):1439-47
pubmed: 10552085
Surgery. 2018 Apr;163(4):761-767
pubmed: 29284590
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1336-1344
pubmed: 30566620
J Nucl Med. 2015 Nov;56(11):1647-53
pubmed: 26272813
Clin Nucl Med. 2017 Jun;42(6):436-443
pubmed: 28263217
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):749-55
pubmed: 18210106
Endocr Relat Cancer. 2020 Mar;27(3):R67-R77
pubmed: 31846429
Eur J Nucl Med Mol Imaging. 2022 May;49(6):1778-1809
pubmed: 35284969
Pituitary. 2006;9(3):243-8
pubmed: 17001462
Front Endocrinol (Lausanne). 2022 Apr 05;13:861434
pubmed: 35450421
Br J Radiol. 2021 Oct 01;94(1126):20210403
pubmed: 34357794
J Clin Oncol. 2018 Sep 1;36(25):2578-2584
pubmed: 29878866
Digestion. 1996;57 Suppl 1:57-61
pubmed: 8813472
J Nucl Med. 2011 Sep;52(9):1361-8
pubmed: 21795361
J Nucl Med. 2019 Jul;60(7):937-943
pubmed: 31263080
J Nucl Med. 2017 Feb;58(2):293-299
pubmed: 27609789
J Clin Oncol. 2005 Apr 20;23(12):2754-62
pubmed: 15837990
Neuroendocrinology. 2020;110(6):517-524
pubmed: 31484182
J Nucl Med. 2020 Feb;61(2):222-227
pubmed: 32015164
Cancers (Basel). 2022 Jan 24;14(3):
pubmed: 35158852
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):934-946
pubmed: 31707430
Cancer Biother Radiopharm. 2015 Aug;30(6):261-9
pubmed: 26181854
J Nucl Med. 2021 Oct;62(10):1406-1414
pubmed: 33579805
Semin Nucl Med. 2020 Mar;50(2):119-123
pubmed: 32172796
J Clin Oncol. 2010 Apr 1;28(10):1652-9
pubmed: 20194865
Pharmaceutics. 2022 Jan 12;14(1):
pubmed: 35057069
N Engl J Med. 1990 Nov 1;323(18):1246-9
pubmed: 2170840
Endocr Relat Cancer. 2019 Nov;26(11):R627-R652
pubmed: 31561209
Cancers (Basel). 2021 Jan 25;13(3):
pubmed: 33503893
J Nucl Med. 2021 Jun 1;62(6):808-815
pubmed: 33067340
Pharmaceuticals (Basel). 2019 Jul 29;12(3):
pubmed: 31362406
Ann N Y Acad Sci. 1994 Sep 15;733:496-506
pubmed: 7978900
Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3203-3214
pubmed: 35230492
N Engl J Med. 1981 Jul 2;305(1):12-7
pubmed: 7231514
BMC Cancer. 2020 Jan 10;20(1):27
pubmed: 31924180
Clin Endocrinol (Oxf). 2019 Dec;91(6):718-727
pubmed: 31569282
J Oncol Pract. 2010 Nov;6(6):e11-6
pubmed: 21358944
JAMA. 1985 May 10;253(18):2741
pubmed: 2859379
Curr Oncol Rep. 2021 Mar 15;23(4):46
pubmed: 33721105
J Nucl Med. 2022 Sep;63(9):1326-1333
pubmed: 34992153
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057
pubmed: 32378020
Lancet Oncol. 2020 Sep;21(9):e431-e443
pubmed: 32888472
Endocr Relat Cancer. 2016 May;23(5):L17-23
pubmed: 26932783
Endocr Relat Cancer. 2019 Aug;26(8):C7-C11
pubmed: 31200364
J Am Med Assoc. 1946 May 11;131:81-6
pubmed: 21025609
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):262-277
pubmed: 28894897
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624
pubmed: 28428192
Sci Rep. 2020 Jun 23;10(1):10196
pubmed: 32576907
Clin Nucl Med. 2022 Jul 1;47(7):599-605
pubmed: 35426841
Endocr Relat Cancer. 2018 Mar;25(3):R115-R130
pubmed: 29233841
Clin Transl Med. 2022 Jul;12(7):e957
pubmed: 35866246
Lancet Oncol. 2021 Dec;22(12):1752-1763
pubmed: 34793718
Endocr Pathol. 2022 Mar;33(1):115-154
pubmed: 35294740
Oncotarget. 2016 May 19;9(19):14791-14802
pubmed: 29599907
J Nucl Med. 2014 Aug;55(8):1248-52
pubmed: 24963127
Endocr Relat Cancer. 2021 Jun 20;28(7):521-527
pubmed: 34010146
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3278-3287
pubmed: 28605448
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
Eur J Nucl Med. 2001 Sep;28(9):1319-25
pubmed: 11585290
J Neuroendocrinol. 2022 Apr;34(4):e13088
pubmed: 35078265
Neuroendocrinology. 2017 Apr 13;105(3):295-309
pubmed: 28402980
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2662-e2670
pubmed: 35380158
Neuroendocrinology. 2014;99(2):108-17
pubmed: 24714208
Trials. 2020 Feb 5;21(1):141
pubmed: 32024533
Cancers (Basel). 2022 Feb 19;14(4):
pubmed: 35205805
J Nucl Med. 2021 Nov;62(11):1571-1581
pubmed: 33674401
BMC Cancer. 2019 Apr 5;19(1):325
pubmed: 30953466
BMC Gastroenterol. 2018 Jun 15;18(1):84
pubmed: 29902988
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169
pubmed: 29484451
EJC Suppl. 2021 Nov 09;16:5-13
pubmed: 34912478
J Clin Endocrinol Metab. 2021 Nov 19;106(12):e4903-e4916
pubmed: 34379772
Eur J Cancer. 2021 Mar;146:56-73
pubmed: 33588146
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Endocr Rev. 2003 Feb;24(1):28-47
pubmed: 12588807
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717
pubmed: 30267116
Endocr Relat Cancer. 2020 Nov;27(11):615-624
pubmed: 33032265
Rev Endocr Metab Disord. 2021 Sep;22(3):495-510
pubmed: 33085037
Endocr Relat Cancer. 2019 Mar;26(3):R145-R156
pubmed: 30608900
Endocr Relat Cancer. 2019 Feb 1;26(2):227-239
pubmed: 30540557
J Clin Endocrinol Metab. 1987 Dec;65(6):1127-34
pubmed: 2824549
Endocr Relat Cancer. 2003 Dec;10(4):451-8
pubmed: 14713257
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638389
Cancer Biother Radiopharm. 1999 Dec;14(6):477-83
pubmed: 10850334
J Nucl Med. 2022 Jul 21;:
pubmed: 35863893
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13639
pubmed: 35735226
Endocr Rev. 2020 Apr 1;41(2):
pubmed: 31555796
J Nucl Med. 2022 Jun 9;:
pubmed: 35680417
Nucl Med Commun. 2019 Dec;40(12):1195-1203
pubmed: 31658219
N Engl J Med. 1983 Dec 22;309(25):1556-63
pubmed: 6140639
Theranostics. 2017 Mar 1;7(5):1149-1158
pubmed: 28435454
Eur J Endocrinol. 2019 Jul;181(1):45-53
pubmed: 31067510
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):453-63
pubmed: 26419852
Clin Cancer Res. 2019 Dec 1;25(23):6939-6947
pubmed: 31439583
Clin Nucl Med. 2017 Nov;42(11):e457-e466
pubmed: 28872545
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3665-e3672
pubmed: 33942075
Cancers (Basel). 2021 Jan 19;13(2):
pubmed: 33561087
Front Horm Res. 2004;31:145-54
pubmed: 14674309
Pharmacol Rev. 2018 Oct;70(4):763-835
pubmed: 30232095
J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S
pubmed: 15653656
Neuroendocrinology. 2017 Mar 30;105(3):212-244
pubmed: 28355596
Neuroendocrinology. 2009;90(2):184-9
pubmed: 19713709
Clin Nucl Med. 2022 Jun 1;47(6):503-511
pubmed: 35507433
J Nucl Med. 2018 Mar;59(3):452-458
pubmed: 28775205
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4016-4027
pubmed: 33903926
Biomed Res Int. 2015;2015:481279
pubmed: 26106608
N Engl J Med. 1983 Dec 15;309(24):1495-501
pubmed: 6139753
Cancer. 2022 Jun 1;128(11):2182-2192
pubmed: 35363879
Neuroendocrinology. 2016;103(5):560-6
pubmed: 26536001
Oncotarget. 2018 Feb 15;9(24):16932-16950
pubmed: 29682195
J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S
pubmed: 28864614